DPhil MBA - Relief Therapeutics Chief Officer

All Insiders . USA . 
Stock . Relief Therapeutics Holding . Stakeholders . Insider . DPhil MBA
RLFTY Stock  USD 5.00  0.68  15.74%   

Insider

DPhil MBA is Chief Officer of Relief Therapeutics Holding
Age 60
Phone41 44 723 59 59
Webhttps://www.relieftherapeutics.com

Relief Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1217) % which means that it has lost $0.1217 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3257) %, meaning that it generated substantial loss on money invested by shareholders. Relief Therapeutics' management efficiency ratios could be used to measure how well Relief Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Relief Therapeutics Holding has accumulated 396 K in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Relief Therapeutics has a current ratio of 2.74, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Relief Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Relief Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Relief Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Relief to invest in growth at high rates of return. When we think about Relief Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

INSIDER Age

Shachar CPAEnlivex Therapeutics
47
Oren HershkovitzEnlivex Therapeutics
47
Moutih RafeiDefence Therapeutics
41
Sigal AradEnlivex Therapeutics
N/A
Sebastien PlouffeDefence Therapeutics
51
Pr MDEnlivex Therapeutics
68
Carrie CesaroneDefence Therapeutics
58
Simon BeaudoinDefence Therapeutics
39
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. Relief Therapeutics is traded on OTC Exchange in the United States. Relief Therapeutics Holding [RLFTY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-0.33
Return On Asset-0.12

Relief Therapeutics Leadership Team

Elected by the shareholders, the Relief Therapeutics' board of directors comprises two types of representatives: Relief Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Relief. The board's role is to monitor Relief Therapeutics' management team and ensure that shareholders' interests are well served. Relief Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Relief Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jeremy CPA, CFO Officer
David McCullough, Sr Access
DPhil MBA, Chief Officer
Jeremy Meinen, Chief Admin
Dorian Bevec, Chief Lifescience
Drew CroninFine, Exec Marketing
Christopher Wick, Sr Sales
Paolo Galfetti, COO Director
Marco Marotta, Chief Officer
Jack Weinstein, Treasurer CFO
Anthony Kim, Sr Operations
Jack MBA, Chief Officer
Serene MPH, VP Medicine

Relief Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Relief Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.33
Return On Asset-0.12
Operating Margin(5.96) %
Current Valuation102.36 M
Shares Outstanding21.96 M
Price To Book0.77 X
Price To Sales19.41 X
Revenue3.32 M
Gross Profit2.57 M
EBITDA(33.3 M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Relief OTC Stock Analysis

When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY